Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Fatigue
Effects of Laughter Yoga on Fatigue, Sleep Quality and Psychological Well-Being in Patients With Multiple Sclerosis: A Randomized Controlled Trial
This study is planned to evaluate the effects of laughter yoga applied to patients with multiple sclerosis on fatigue, sleep quality and psychological well-being.
- Conditions
- Multiple Sclerosis, Fatigue, Sleep Quality, Psychological Well-being
- Trial name
- NCT06783413
- Testing
- Intervention group (Laughter Yoga), Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Tokat Gaziosmanpasa University
Vestibular Rehabilitation in MS
Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis
The Cawthorne Cooksey exercises and conventional program of physical therapy were administered.
- Trial name
- NCT05635890
- Testing
- Cawthorne Cooksey exercise protocol, conventional vestibular rehabilitation
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- October 6 University
Multiple Sclerosis
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple…
- Trial name
- NCT00246324
- Testing
- Interferon beta 1a, oral doxycycline
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Multiple Sclerosis, Relapsing-Remitting
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active…
- Trial name
- NCT00050778
- Testing
- Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
- Where
- 49 sites in United States, Croatia and 3 more
- Volunteers
- 334 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Pelvic Floor Dysfunction
Relationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients
we aim to investigate the relationship between pelvic floor dysfunctions, core endurance, hip external rotation muscle strength, and tibialis posterior and tibialis anterior muscle activation in patients diagnosed with MS
- Trial name
- NCT06777134
- Testing
- Assessment of pelvic floor dysfunction, The Quality of Life Assessment, Core endurance assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 73 people
- Sponsor
- Berivan Beril Kılıç
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system that causes disability in young adults.
- Trial name
- MS-SEP (NCT03655093)
- Testing
- Validation of AMSQ questionnaire
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Rennes University Hospital
RELAPSING REMITTING MULTIPLE SCLEROSIS
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion.
- Trial name
- NCT02833714
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis
Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS)
This project will evaluate a new therapy for patients with a severe form of MS known as progressive MS. These patients are severely limited in their ability to walk and function in everyday life.
- Trial name
- NCT01097538
- Testing
- Body-weight supported treadmill training, Total body recumbent stepper training
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Hicks, Audrey, Ph.D.
Multiple Sclerosis, Relapsing-Remitting
Rehabilitation Study in MS Patients
Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.
- Trial name
- NCT00780455
- Testing
- Interferon beta-1b, FRP within 15 days after randomization, Interferon beta-1b, FRP about 6 weeks after randomization
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Bayer
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.
ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be included on a voluntary basis. We plan to include a group of approximately 20 patients with MS.
- Trial name
- NCT04888689
- Testing
- Actimyo°, IMU
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Laurent Servais
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- 2 sites in Czechia, Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
There are two standard and a few second line treatments for RRMS. Since the disease cannot be cured by these existing treatments and all treatment options have significant limitations, there is the need to develop new treatment…
- Trial name
- RESI (NCT02364986)
- Testing
- Rebif®, Avonex
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PD Dr. Marcus Müller
Multiple Sclerosis, Relapsing-remitting
Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis
A mixed methods randomized controlled trial pilot study to assess peer support impact on relapsing-remitting multiple sclerosis patients' therapeutic adherence.
- Trial name
- PAIR-SEP (NCT05519553)
- Testing
- Peer support
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
Secondary Progressive Multiple Sclerosis
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to…
- Trial name
- NCT01665144
- Testing
- BAF312
- Where
- 290 sites in United States, Argentina and 29 more
- Volunteers
- 1,651 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis
An open prospective study with multiple (every 6-12 months) intrathecal or intravenous injections of autologous MSC in patients with progressive forms of MS (secondary progressive, primary progressive or relapsing-progressive)…
- Trial name
- MSC-pMS (NCT04823000)
- Testing
- Mesenchymal Stem Cells (MSC)
- Volunteers
- 24 people
- Sponsor
- Hadassah Medical Organization
Amyotrophic Lateral Sclerosis (ALS)
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function.
- Trial name
- NCT01232738
- Testing
- rasagiline
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Yunxia Wang, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.